Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
about
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.B cell receptor signaling regulates metabolism in Chronic Lymphocytic Leukemia.Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.Drug-perturbation-based stratification of blood cancer.The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.IGHV mutational status testing in chronic lymphocytic leukemia.Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.Chronic lymphocytic leukaemia
P2860
Q33774517-04229A49-779F-4D86-9D85-67AF8B4A1F46Q37694617-89F8B1BF-42CC-4ED9-BAF4-C910E3F38820Q37706530-567846FA-680D-4E44-9718-B3A6D97492E8Q38611244-A2542B0F-74B0-419B-9419-D2C2543FC9E8Q38809539-9A17BD42-BF0B-414B-9B1D-5E74988C6094Q41848521-F725C956-3C2D-4AC9-A94A-76F4341161EBQ42315534-EB95A1ED-620B-434B-B528-4835506118BDQ47331796-761F9714-517B-44B7-BAE6-ED9BEE2A224BQ48181248-19A064AE-7230-4F33-BF28-79B6F3A71651Q48315296-45395E8D-5D69-4FC1-9F31-92FD146FD6FDQ49912101-5C84B42D-722B-4845-9E5E-BA0DE21FB6ABQ51173647-40279F4C-F570-492C-B29D-B643AE8D4A5CQ53963822-F42965B8-7DE9-4926-9029-B0DA26A496ACQ55061968-6E3FAE98-B6B1-4446-8407-3209CDEAF35AQ56270980-7F89CE05-C6D9-4E1C-AE80-5DCFF2C1C541
P2860
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Heightened BTK-dependent cell ...... eased sensitivity to ibrutinib
@en
type
label
Heightened BTK-dependent cell ...... eased sensitivity to ibrutinib
@en
prefLabel
Heightened BTK-dependent cell ...... eased sensitivity to ibrutinib
@en
P2093
P2860
P356
P1433
P1476
Heightened BTK-dependent cell ...... eased sensitivity to ibrutinib
@en
P2093
Chadi Nabhan
Morton Coleman
Natalie Galanina
Sonali M Smith
P2860
P304
P356
10.18632/ONCOTARGET.6727
P407
P50
P577
2015-12-22T00:00:00Z